Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Jan 31:(1):CD008900.
doi: 10.1002/14651858.CD008900.pub2.

Cerebrolysin for vascular dementia

Ning Chen  1 , Mi Yang, Jian Guo, Muke Zhou, Cairong Zhu, Li He
Affiliations
Meta-Analysis

Cerebrolysin for vascular dementia

Ning Chen et al. Cochrane Database Syst Rev. .

Update in

  • Cerebrolysin for vascular dementia.
    Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cui S, et al. Cochrane Database Syst Rev. 2019 Nov 11;2019(11):CD008900. doi: 10.1002/14651858.CD008900.pub3. Cochrane Database Syst Rev. 2019. PMID: 31710397 Free PMC article.

Abstract

Background: Vascular dementia is a common disorder without definitive treatments. Cerebrolysin seems to be a promising intervention based on its potential neurotrophic and pro-cognitive effects, but studies of its efficacy have yielded inconsistent results.

Objectives: To assess the efficacy and safety of Cerebrolysin for vascular dementia.

Search methods: We searched ALOIS - the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 4 November 2012 using the terms: Cerebrolysin, Cere, FPF1070, FPF-1070. ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases, numerous trial registries and grey literature sources.

Selection criteria: All randomized controlled trials of Cerebrolysin for treating vascular dementia without language restriction.

Data collection and analysis: Two authors independently selected trials and evaluated the methodological quality, then extracted and analysed data from the included trials.

Main results: Six randomized controlled trials with a total of 597 participants were eligible. The meta-analyses revealed a beneficial effect of Cerebrolysin on general cognitive function measured by mini-mental state examination (MMSE) (weighted mean difference (WMD) 1.10; 95% confidence interval (CI) 0.37 to 1.82) or Alzheimer's Disease Assessment Scale Cognitive Subpart, extended version (ADAS-cog+) (WMD -4.01; 95% CI -5.36 to -2.66). It also improved patients' global clinical function evaluated by the response rates (relative risk (RR) 2.71, 95% CI 1.83 to 4.00). Only non-serious adverse events were observed in the included trials, and there was no significant difference in occurrence of non-serious side effects between groups (RR 0.97, 95% CI 0.49 to 1.94).

Authors' conclusions: Cerebrolysin may have positive effects on cognitive function and global function in elderly patients with vascular dementia of mild to moderate severity, but there is still insufficient evidence to recommend Cerebrolysin as a routine treatment for vascular dementia due to the limited number of included trials, wide variety of treatment durations and short-term follow-up in most of the trials.

PubMed Disclaimer

MeSH terms

LinkOut - more resources